BrightSpring Health Services, Inc.

BTSG

CIK 0001865782 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$3.55B
↑+91.0% +$1.69Bvs FY2024 (Q4)
Operating Income
$108M
Net Income
$50M
Gross Profit
$413M
↑+313.0% +$313Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
61/100
  • Profitability
    1ROIC 5.2% (10% = solid, 20%+ = moat)
  • Liquidity
    53Current Ratio 1.57 (above 1.5 = solid)
  • Leverage
    33D/E 1.34 (under 0.5 = conservative)
  • Efficiency
    100Asset Turnover 2.09x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +91.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    76Op Margin 3.0% · trend +1.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project BTSG's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$30.89
Total enterprise IV
$6.79B
Diluted shares
0.22B
Terminal PV
$4.92B (72% of total)
Year-5 FCF
$580M
YearProjected FCFDiscounted PV
+1$426M$388M
+2$460M$380M
+3$497M$374M
+4$537M$367M
+5$580M$360M
Terminal$7.93B$4.92B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$95M
investment in PP&E
Stock buybacks (TTM)
$43M
share count reduction
Stock-based comp (TTM)
$70M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$6.41B
everything owned
Total liabilities
$4.53B
everything owed
Stockholders' equity
$1.88B
shareholder claim
Net debt
$2.42B
LT debt minus cash

Recent performance · 13 quarters

Revenue↑+91.0% +$1.69B
$3.55B
Net Income
$77M
Free Cash Flow↑+157.5% +$119M
$194M
Operating Margin
3.0%

Drill down